Modelos para implementar a vacinação contra dengue by Amaku, Marcos et al.
Rev. Inst. Med. Trop. Sao Paulo
54(Suppl. 18):S18-S21, October, 2012
Presented at the I International Symposium on Dengue of the School of Medicine University of São Paulo on October 6, 2011.
(1) School of Veterinary Medicine, University of São Paulo, Brazil.
(2) Dengue Company, Sanofi Pasteur 2 Avenue Pont Pasteur 69007 Lyon, France.
(3) School of Medicine, University of Sao Paulo and LIM 01-HCFMUSP, Brazil.
(4) London School of Hygiene and Tropical Medicine, London University, UK.
Correspondence to: Eduardo Massad. E-mail: edmassad@usp.br
DESIGNING A VACCINATION STRATEGY AGAINST DENGUE
Marcos AMAKU(1), Laurent COUDEVILLE(2) & Eduardo MASSAD(3,4)
SUMMARY
In this work we propose a mathematical approach to estimate the dengue force of infection, the average age of dengue first infection, 
the optimum age to vaccinate children against dengue in a routine fashion and the optimum age interval to introduce the dengue 
vaccine in a mass vaccination campaign. The model is based on previously published models for vaccination against other childhood 
infections, which resulted in actual vaccination programmes in Brazil. The model was applied for three areas of distinct levels of 
endemicity of the city of Recife in Northeastern State of Pernambuco, Brazil. Our results point to an optimal age to introduce the 
dengue vaccine in the routine immunization programme at two years of age and an age interval to introduce a mass vaccination 
between three and 14 years of age.
INTRODUCTION
No medical intervention has such an unambiguous track record of 
preventing morbidity and mortality from infectious diseases than that 
of vaccines1.
While a live-attenuated vaccine exists since decades against the 
prototype flavivirus, yellow fever virus, there is an urgent need for 
vaccines against dengue2.
Vaccine candidates against dengue include live, attenuated vaccines 
obtained via cell passages or by recombinant DNA technology, 
and subunit vaccines3. Some candidate vaccines composed by four 
recombinant live attenuated vaccines based on a yellow fever vaccine 
17D backbone are currently under clinical tests2-7.
The ideal dengue vaccine should be, first of all, safe8, that is, the 
vaccine must not only be weakly or non-reactogenic, sterile, and pure, 
but it must also be functionally tetravalent to avoid the theoretical risk 
of antibody-mediated immune enhancement, or antibody-dependent 
enhancement (ADE). The phenomenon of ADE is a viral replicative 
enhancement due to the presence of subneutralizing heterotypic 
antibody9. Thus, an individual previously infected with a given dengue 
serotype is likely to develop a more severe disease when infected with 
a second different serotype.
In this article we propose a mathematical framework to calculate the 
optimum age to introduce a dengue vaccine based on the age-dependent 
seroprevalence profile of a given population, as well as the age interval 
to mass vaccinate a target population in a campaign. The model is based 
on previously published models for vaccination against other childhood 
infections10,11, which resulted in actual vaccination programmes in 
Brazil. The model was applied for three areas of distinct levels of 
endemicity of the city of Recife in Northeastern State of Pernambuco, 
Brazil12. Our results point to an optimal age to introduce the dengue 
vaccine in the routine immunization programme at two years of age 
and an age interval to introduce a mass vaccination between three and 
14 years of age.
METHODS
Fitting seroprevalence data
 Let S+(a) be the proportion of individuals with age a who are 
seropositive to any dengue serotype. The estimated function S+(b) that 
results from the fitting of seroprevalence data is given by: 
 (1)
where k1 and k2 are the fitting parameters estimated either by Maximum 
Likelihood or by the Least Squares method.
The estimated values of parameters k1 and k2 fitted to the 
seroprevalence profile of three areas of the city of Recife12, the capital 
of the Pernambuco State at the northeastern part of Brazil, are shown in 
Table 1. The fitted curves can be seen in Figure 1.
In our model the seropositive individuals are those who are either 
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still infected by any of the dengue viruses or are recovered and immune 
from previous infections.
Calculation of the force of infection and the average age of first 
infection
The force of infection, estimated from the seroprevalence data can 
be calculated by the catalytic method as: 
 (2)
Equation (2), expressed in terms of equation (1), results in:
  (3)
The result of the estimation of the force of infection for the three 
areas analyzed can be seen in Figure 2 and in Table 2.
From the force of infection we can define the average age of first 
infection, –a13: 
 (4)
where S–(a) = 1 – S–(a)  is the age-dependent proportion of susceptibles.
The superior limit of age (L = 40 years) was considered as the superior 
limit of integration of equation (4).
The average age of first, –a, and the average force of infection, –l, are 
related to each other according to14:
  (5)
The results of the calculation of the age of first, –a, and the average 
force of infection, –l, for the three areas analyzed can be seen in Table 2.
Calculation of the optimal age to vaccinate against dengue
From the force of infection calculated as above we can estimate the 
optimal age to routinely vaccinate the target population according to the 
following equation15:
 (6)
where E is the life-time risk of acquiring the infection, the function C(a) 
is the age-dependent seroconversion to the vaccine and the function R(a) 
is some function of the age-dependent “undesirability” of the disease, 
estimated from the clinical gravity of dengue for age stratum. 
Figure 3 shows the vaccine seroconversion function C(a). This 
function takes into account two factors: the protection conferred by 
maternal antibodies that lasting on average five to nine months according 
to the serotype16 and the immune response observed after vaccination, 
quite similar for children between two to five years of age and older 
children3,6. As a consequence we considered that the seroconversion rate 
plateaus from two years of age.
R(a), the disease “undesirability” was assumed 1 for all ages. 
Figure 4 show the results of the estimated optimal age to introduce 
Fig. 1 - Fitting seroprevalence data of the three areas analysed to equation 1.
Table 1
Fitting parameters (^k1 and 
^
k2) for the three areas of Recife
Area of Recife  ^k1 (years-2)  
^k2 (years-1)
Brasília Teimosa 0.1229 0.1829
Engenho do Meio 0.1025 0.1912
Casa Forte 0.1266 0.2879
Fig. 2 - The force of infection for the three regions analysed, calculated according to 
equation (3)
Table 2
Average force of infection and average age of first infection for the three areas 
of Recife
Area of Recife  –l (years-1)  –a (years)
Brasília Teimosa 0.1185 8.5
Engenho do Meio 0.09 11
Casa Forte 0.05 19
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Fig. 3 - Age-dependent seroconversion curve.
the first dose of the vaccine in the vaccination calendar in the three 
studied areas. 
As it can be seen from the figures the optimal age to introduce the 
first dose for the three areas is two years of age.
After the introduction of the vaccine in the vaccination calendar, it 
is possible to estimate the impact of an eventual catch-up campaign for 
several alternative age intervals, according to10:
 (7)
where nis the vaccination rate, µ is the mortality rate of the population,
 
p 
is the proportion of children vaccinated and (a2 – a1) the age interval of 
the campaign. This is calculated according to the following expressions10:
  (8)
Fig. 4 - Estimated optimal age to introduce the first dose of the vaccine in the vaccination 
calendar in the three studied areas, according to equation (6).
Fig. 5 - The impact of a vaccination campaign for several age intervals and several vaccination 
coverage proportions, according to equations (7) and (8).
Figure 5 shows the impact of a vaccination campaign for several age 
intervals and several vaccination coverage proportions.
As it can be observed from the figure, the age interval with the greater 
impact on the force of infection, considering 80% vaccination coverage, 
is between three and 14 years of age.
 
DISCUSSION
The development of a dengue vaccine has been a challenge for 
decades. Currently, some candidate products are being tested in clinical 
trials revealing promising results.
The present work simulates different scenarios departing from the 
characteristics currently known for existing vaccines, and varies age at 
vaccination, vaccine efficacy and mixing patterns. From those quantitative 
calculations the impact on dengue force of infection and lifetime expected 
risk was verified.
Our results indicate that the optimal age for a single vaccination 
interval is two years of age if there is no immunity waning. The lifetime 
expected risk of dengue acquisition calculation allowed to estimate 
this optimum age to introduce the vaccine in a routine immunization 
calendar. The optimum age interval to introduce the vaccine in a mass 
vaccination campaign was estimated to be between three and 14 years 
of age.
The calculations carried out in this study have some important 
limitations that should be highlighted, in particular the assumption of an 
endemic equilibrium that allows the estimation of the force of infection 
from a seroprevalence profile. Dengue is an infection that presents a 
marked seasonality and an incidence that varies from year to year. 
However, in the absence of a better alternative, and as a first 
approximation, the methods and assumptions applied here can provide a 
reliable indication on the best strategy to introduce a new vaccine, such as 
the dengue one. For a more accurate designing of vaccination strategies, 
new mathematical methods would be required, which could provide a 
detailed analysis of the disease dynamics in two dimensions, namely age 
and time. Alternatively, numerical simulations methods could provide a 
practical test bench to analyse possible vaccination strategies by taking 
both time age dimensions into account.
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Finally, we should comment on the fact that we consider all dengue 
serotypes in our analyses. This is due to the fact that the most advanced 
vaccines on trial currently are tetravalent and therefore there is no need to 
differentiate the serotypes at this moment. Notwithstanding, an analysis 
differentiating the four distinct serotypes could be easily done on the 
mathematical framework proposed in this paper.
As mentioned above, this work was intended to provide a first 
approximation to the complex task of determining the best strategy to 
introduce the dengue vaccine in the affected areas. We hope the estimation 
presented here can help the health authorities to design the best strategy 
for dengue vaccination.
RESUMO
Modelos para implementar a vacinação contra dengue
Neste trabalho propomos um modelo matemático para a estimativa 
da força de infecção, da idade média de primo-infecção, da idade ótima 
para vacinação de rotina e do intervalo ótimo de cobertura vacina em uma 
campanha para a introdução da vacina contra a dengue. O modelo baseia-
se em publicações anteriores de desenhos de estratégias de vacinação 
contra outras infecções e que resultaram em estratégias de vacinação no 
Brasil. O modelo foi aplicado em três áreas com níveis endêmicos de 
dengue distintos na cidade de Recife, Pernambuco. Nossos resultados 
apontam para uma idade ótima de vacinação na rotina de dois anos de 
idade e para um intervalo de vacinação em campanha entre três e 14 anos.
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